Korro Bio (NASDAQ:KRRO) Announces Earnings Results, Beats Estimates By $0.07 EPS

Korro Bio (NASDAQ:KRRO) released its earnings results on Tuesday. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.33) by $0.07, Zacks reports. The firm had revenue of $2.27 million for the quarter.

Korro Bio Stock Performance

Shares of NASDAQ KRRO opened at $24.17 on Wednesday. Korro Bio has a one year low of $18.50 and a one year high of $98.00. The business has a 50-day moving average price of $30.70 and a two-hundred day moving average price of $41.82.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on KRRO. HC Wainwright reaffirmed a “buy” rating and set a $115.00 target price on shares of Korro Bio in a report on Friday, November 22nd. Oppenheimer initiated coverage on Korro Bio in a research report on Friday, January 10th. They issued an “outperform” rating and a $155.00 price target for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Korro Bio presently has an average rating of “Buy” and a consensus price target of $144.00.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).